Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

81.80EUR
11:39am EDT
Change (% chg)

€-0.44 (-0.54%)
Prev Close
€82.24
Open
€82.14
Day's High
€82.65
Day's Low
€81.63
Volume
1,642,238
Avg. Vol
2,434,670
52-wk High
€92.97
52-wk Low
€66.72

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €103,824.10
Shares Outstanding(Mil.): 1,262.45
Dividend: 2.96
Yield (%): 3.60

Financials

  SASY.PA Industry Sector
P/E (TTM): 22.23 31.70 32.82
EPS (TTM): 3.70 -- --
ROI: 5.69 15.41 14.97
ROE: 8.50 16.43 16.21

BRIEF-Paulson & Co cuts share stake in Teva Pharmaceutical, Sanofi

* Paulson & Co Inc cuts share stake in Teva Pharmaceutical Industries Ltd by 38.7 percent to 6.7 million sponsored ADR - SEC filing

Aug 14 2017

BRIEF-Sanofi files suit in U.S. to defend patent rights on Lantus

* REG-SANOFI FILES SUIT IN THE U.S. TO DEFEND ITS PATENT RIGHTS ON LANTUS

Aug 08 2017

BRIEF-Sanofi files suit in U.S. to defend patent rights on Lantus

* Sanofi files suit in the U.S. to defend its patent rights on Lantus

Aug 08 2017

Drugmakers' hopes for gene therapy rise despite tiny sales in Europe

LONDON The science of gene therapy is finally delivering on its potential, and drugmakers are now hoping to produce commercially viable medicines after tiny sales for the first two such treatments in Europe.

Aug 08 2017

Drugmakers' hopes for gene therapy rise despite tiny sales in Europe

LONDON, Aug 8 The science of gene therapy is finally delivering on its potential, and drugmakers are now hoping to produce commercially viable medicines after tiny sales for the first two such treatments in Europe.

Aug 08 2017

Regeneron beats profit view, to end antibody deal with Sanofi

Regeneron Pharmaceuticals Inc reported a much better-than-expected quarterly profit on strong demand for its flagship Eylea drug and said it would end one of its agreements with France's Sanofi SA to develop antibodies by the end of the year.

Aug 03 2017

UPDATE 4-Regeneron beats profit view, to end antibody deal with Sanofi

* Shares close down 2 pct on plans to scrap antibody deal (Adds details about Sanofi antibody deal, Sanofi and analyst comments, updates shares)

Aug 03 2017

BRIEF-Sanofi genzyme says PEI Pharmacare has added Lemtrada to pharmacare formulary

* Sanofi Genzyme says PEI Pharmacare has added Lemtrada to pharmacare formulary Source text for Eikon: Further company coverage:

Aug 01 2017

BRIEF-Sanofi strengthens relationship with Evidation Health

* SAID ON MONDAY IT STRENGTHENS RELATIONSHIP WITH EVIDATION HEALTH Source text: http://bit.ly/2vj4M2W Further company coverage: (Gdynia Newsroom)

Aug 01 2017

BRIEF-Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes

* Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes

Jul 31 2017

Earnings vs. Estimates